Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 4OTHER 3INDUSTRY 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Central Nervous System Neoplasms 27Astrocytoma 15Oligodendroglioma 14Glioblastoma 14Gliosarcoma 12Glioma 11Brain Neoplasms 11Ependymoma 4Spinal Cord Neoplasms 3Neuroblastoma 3Somatostatinoma 2Neoplasm Metastasis 2Melanoma 2Medulloblastoma 2Lymphoma 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenoma, Islet Cell 2Sarcoma, Ewing 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Optic Nerve Glioma 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive 1Leukemia 1Insulinoma 1Glucagonoma 1Glioma, Subependymal 1Gastrointestinal Stromal Tumors 1Gastrinoma 1

Interventions

Vincristine 3Thiotepa 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Cyclophosphamide 2Cisplatin 2Carboplatin 2ribociclib 1merphos 1lonafarnib 1etoposide phosphate 1Topotecan 1Temozolomide 1Stem Cell Transplantation 1Radiotherapy, Conformal 1Radiotherapy 1Psychiatric Rehabilitation 1Platinum 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Neoadjuvant Therapy 1Methotrexate 1Leucovorin 1Irinotecan 1Immunohistochemistry 1Gene Expression Profiling 1Everolimus 13-(4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Rhabdoid Tumor × Temozolomide × Clear all
NCT00138216 2023-10-02

Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors

Children's Oncology Group

Phase 1 Completed
42 enrolled
CNS

Familial ependymoma, Astrocytoma, Medulloblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Rhabdoid Tumor, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡